Alpha memo: glutathione inflammation pilot clinical context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Narrow the alpha to one specific bounded signal — e.g., 'GlyNAC corrects intracellular GSH deficiency in older adults within a 24-week pilot window, with downstream effects on oxidative stress and inflammation that remain to be tested in RCTs' — rather than listing nine endpoints.
2. Reframe the 'Why this is surprising' section to acknowledge that Receipt 1 and Receipt 2 are from the same research lineage; reframe as 'within-lab extension/replication' rather than 'cross-context signal' if that is what the evidence supports.
3. Reconcile the 'design-stage' characterization of Receipt 1 with its abstract content, which reports completed OA vs YA comparisons.
4. Sharpen the falsifier to name the specific GlyNAC dose/duration used in Receipt 2 (e.g., 24 weeks at 1.33 mmol/kg/day glycine + 0.81 mmol/kg/day NAC) so the prediction is concretely falsifiable.

Major issues

• The memo's title and one-sentence alpha frame a 'glutathione inflammation pilot clinical context boundary,' but the signal itself is not clearly bounded — it covers intracellular GSH deficiency, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genomic damage, strength, gait-speed, cognition, and body composition. The bounded 'one research signal' is unclear; the memo needs to specify which single signal is being mapped.
• The 'Why this is surprising' rationale is weak: Receipt 1 is a 2024 protocol/design-stage pilot report from the same research group as Receipt 2, and pairing a completed 2021 pilot with a 2024 design-stage paper from the same lab is not an independent cross-context replication — it is largely an extension/replication by the same group. The memo should reframe this honestly rather than calling it 'analogous cross-context signal.'

Minor issues

• Receipt 1 abstract excerpt indicates 'compared to YA, OA had evidence of cognitive decline' — Receipt 1 appears to report completed results, not just a protocol. The memo should reconcile this by reading the full abstract rather than calling it 'design-stage.'
• The phrase 'cognitive decline' in the title appears as an endpoint in both receipts, but the alpha sentence focuses on GSH deficiency — the title/signal alignment is loose.
• Minor: the falsifier criterion ('sufficiently powered RCT failing to change intracellular GSH deficiency') is reasonable but could specify the dose and duration used in Receipt 2 for falsifiability.

Reviewer note

The memo correctly anchors on two GlyNAC pilot receipts and avoids overclaiming beyond the evidence — it explicitly states these are pilot-scale, single-arm, short-duration signals and refuses to issue clinical or dosing recommendations. Hedging language ('may correct,' 'bounded by,' 'rather than refuted') is appropriate and proportional to the cited evidence. Source-grounding is solid: both receipts exist, are recent (2021 and 2024), and directly describe the GlyNAC pilot findings the memo summarizes. However, three issues push this toward revise rather than accept: (1) the bounded 'one research signal' is not actually one — the memo carries nine endpoints without clearly selecting which signal is the alpha; (2) the 'cross-context' framing overstates independence since both receipts come from the same research group (Sekhar lab), making this an in-lab extension rather than independent replication; and (3) Receipt 1's abstract reports completed OA-vs-YA cognitive decline findings, which contradicts the memo's 'design-stage pilot' characterization. These are bounded fixes — narrowing the alpha signal, reframing the cross-context language, and reconciling the protocol characterization — not a scope reset, so revise is the correct call.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis